Could a red algae mineral help tame ulcerative colitis?
NCT ID NCT03869905
First seen Jun 24, 2026 · Last updated Aug 26, 2026 · Updated 3 times
Summary
This phase 2 trial tests Aquamin, a mineral supplement made from red marine algae, in 40 people with mild ulcerative colitis or those in remission. Researchers want to see if it improves symptoms, reduces inflammation, and helps maintain remission. Participants take 4 capsules daily for a set period, and the study measures quality of life, disease activity, and inflammatory markers.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Aquamin (a multi-mineral supplement from red marine algae)
- What this could lead to
- If it works, this could offer a natural, over-the-counter option to help manage ulcerative colitis symptoms and maintain remission.
- What could go wrong
- This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The supplement is not a proven treatment and may not work better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2019
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Ulcerative colitis with confirmed diagnosis by histology and endoscopy AND in stable remission for 3 months or more without therapy or with maintenance therapy (except steroids and antibiotics for 3 months) OR having a mild disease. * A negative pregnancy test Exclusion Criteria: * No history or diagnosis of any of the following conditions: Crohn's disease, bleeding disorders, gastrointestinal or colonic malignancy, Kidney disease, including kidney "stones" or hypercalcemia, Coagulopathy/hereditary hemorrhagic disorders/ or receiving therapeutic doses of Coumadin or heparin. * Ingested certain medications (Calcium, Vitamin D, fiber supplements and Non-steroidal anti-inflammatory drugs - NSAIDs) within 30 days of study start.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ulcerative colitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ulcerative colitis drugs put under the microscope for hidden clot risk
- Can a cheap Anti-Inflammatory drug calm ulcerative colitis?
- Which IBD therapy works best for kids? researchers compare two approaches
- Can trained peer mentors ease the mental toll of IBD?
- Can a new infusion drug calm ulcerative colitis?
- A breath test for gut disease? researchers hunt for invisible clues